Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders

ACS Medicinal Chemistry Letters

Volumn 8, Issue 6, 2017, Pages 618-621

  Puleo, David E ^a   Kucera, Kaury ^a   Hammarén, Henrik M ^c   Ungureanu, Daniela ^c   Newton, Ana S ^b   Silvennoinen, Olli ^c   Jorgensen, William L ^b   Schlessinger, Joseph ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

JAK2; JH2; MPN; Pseudokinase; Small molecule

Indexed keywords

JANUS KINASE 2;

ARTICLE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN STRUCTURE;

EID: 85020466558     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.7b00153     Document Type: Article

References (19)

1. O'Shea, J. J.; Holland, S. M.; Staudt, L. M. JAKs and STATs in immunity, immunodeficiency, and cancer N. Engl. J. Med. 2013, 368, 161-70 10.1056/NEJMra1202117
2. O'Shea, J. J.; Schwartz, D. M.; Villarino, A. V.; Gadina, M.; McInnes, I. B.; Laurence, A. The JAK-STAT pathway: impact on human disease and therapeutic intervention Annu. Rev. Med. 2015, 66, 311-28 10.1146/annurev-med-051113-024537
3. Saharinen, P.; Takaluoma, K.; Silvennoinen, O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain Mol. Cell. Biol. 2000, 20, 3387-95 10.1128/MCB.20.10.3387-3395.2000
4. Saharinen, P.; Vihinen, M.; Silvennoinen, O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain Mol. Biol. Cell 2003, 14, 1448-59 10.1091/mbc.E02-06-0342
5. Lupardus, P. J.; Ultsch, M.; Wallweber, H.; Bir Kohli, P.; Johnson, A. R.; Eigenbrot, C. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition Proc. Natl. Acad. Sci. U. S. A. 2014, 111, 8025-30 10.1073/pnas.1401180111
6. Shan, Y.; Gnanasambandan, K.; Ungureanu, D.; Kim, E. T.; Hammaren, H.; Yamashita, K.; Silvennoinen, O.; Shaw, D. E.; Hubbard, S. R. Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase Nat. Struct. Mol. Biol. 2014, 21, 579-84 10.1038/nsmb.2849
7. Baxter, E. J.; Scott, L. M.; Campbell, P. J.; East, C.; Fourouclas, N.; Swanton, S.; Vassiliou, G. S.; Bench, A. J.; Boyd, E. M.; Curtin, N.; Scott, M. A.; Erber, W. N.; Green, A. R.; Cancer Genome, P. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders Lancet 2005, 365, 1054-61 10.1016/S0140-6736(05)74230-6
8. James, C.; Ugo, V.; Le Couedic, J. P.; Staerk, J.; Delhommeau, F.; Lacout, C.; Garcon, L.; Raslova, H.; Berger, R.; Bennaceur-Griscelli, A.; Villeval, J. L.; Constantinescu, S. N.; Casadevall, N.; Vainchenker, W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera Nature 2005, 434, 1144-8 10.1038/nature03546
9. Kralovics, R.; Passamonti, F.; Buser, A. S.; Teo, S. S.; Tiedt, R.; Passweg, J. R.; Tichelli, A.; Cazzola, M.; Skoda, R. C. A gain-of-function mutation of JAK2 in myeloproliferative disorders N. Engl. J. Med. 2005, 352, 1779-90 10.1056/NEJMoa051113
10. Levine, R. L.; Wadleigh, M.; Cools, J.; Ebert, B. L.; Wernig, G.; Huntly, B. J.; Boggon, T. J.; Wlodarska, I.; Clark, J. J.; Moore, S.; Adelsperger, J.; Koo, S.; Lee, J. C.; Gabriel, S.; Mercher, T.; D'Andrea, A.; Frohling, S.; Dohner, K.; Marynen, P.; Vandenberghe, P.; Mesa, R. A.; Tefferi, A.; Griffin, J. D.; Eck, M. J.; Sellers, W. R.; Meyerson, M.; Golub, T. R.; Lee, S. J.; Gilliland, D. G. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Cancer Cell 2005, 7, 387-97 10.1016/j.ccr.2005.03.023
11. Toms, A. V.; Deshpande, A.; McNally, R.; Jeong, Y.; Rogers, J. M.; Kim, C. U.; Gruner, S. M.; Ficarro, S. B.; Marto, J. A.; Sattler, M.; Griffin, J. D.; Eck, M. J. Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases Nat. Struct. Mol. Biol. 2013, 20, 1221-3 10.1038/nsmb.2673
12. Ungureanu, D.; Wu, J.; Pekkala, T.; Niranjan, Y.; Young, C.; Jensen, O. N.; Xu, C. F.; Neubert, T. A.; Skoda, R. C.; Hubbard, S. R.; Silvennoinen, O. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling Nat. Struct. Mol. Biol. 2011, 18, 971-6 10.1038/nsmb.2099
13. Bandaranayake, R. M.; Ungureanu, D.; Shan, Y.; Shaw, D. E.; Silvennoinen, O.; Hubbard, S. R. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F Nat. Struct. Mol. Biol. 2012, 19, 754-9 10.1038/nsmb.2348
14. Min, X.; Ungureanu, D.; Maxwell, S.; Hammaren, H.; Thibault, S.; Hillert, E. K.; Ayres, M.; Greenfield, B.; Eksterowicz, J.; Gabel, C.; Walker, N.; Silvennoinen, O.; Wang, Z. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2) J. Biol. Chem. 2015, 290, 27261-70 10.1074/jbc.M115.672048
15. Hammaren, H. M.; Ungureanu, D.; Grisouard, J.; Skoda, R. C.; Hubbard, S. R.; Silvennoinen, O. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 4642-7 10.1073/pnas.1423201112
16. Lin, R.; Connolly, P. J.; Huang, S.; Wetter, S. K.; Lu, Y.; Murray, W. V.; Emanuel, S. L.; Gruninger, R. H.; Fuentes-Pesquera, A. R.; Rugg, C. A.; Middleton, S. A.; Jolliffe, L. K. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities J. Med. Chem. 2005, 48, 4208-11 10.1021/jm050267e
17. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26, 127-32 10.1038/nbt1358
18. Howard, S.; Berdini, V.; Boulstridge, J. A.; Carr, M. G.; Cross, D. M.; Curry, J.; Devine, L. A.; Early, T. R.; Fazal, L.; Gill, A. L.; Heathcote, M.; Maman, S.; Matthews, J. E.; McMenamin, R. L.; Navarro, E. F.; O'Brien, M. A.; O'Reilly, M.; Rees, D. C.; Reule, M.; Tisi, D.; Williams, G.; Vinkovic, M.; Wyatt, P. G. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity J. Med. Chem. 2009, 52, 379-88 10.1021/jm800984v
19. Dusa, A.; Mouton, C.; Pecquet, C.; Herman, M.; Constantinescu, S. N. JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitors PLoS One 2010, 5, e11157 10.1371/journal.pone.0011157